$eypt
$EYPT sees a surge in engagements on X, driven by discussions around institutional buying and a promising cancer drug development. The community is buzzing with positive sentiment.
About $eypt
$EYPT refers to the digital ecosystem and community surrounding a decentralized social media platform.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Month: [-------] +29%
[--] Months: [-------] +27%
[--] Year: [---------] -4%
1-Year High: [-------] on 2025-03-05
1-Year Low: [--] on 2025-05-04
Engagements by network (24h): Reddit: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-25
1-Year Low: [--] on 2025-10-09
Mentions by network (24h): Reddit: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $eypt in the last [--] hours which is down 23% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-10-05
The most influential creators that mention $eypt in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @plainyogurt21 | [--] | [-----] | [--] | [-----] |
| @Quantumup1 | [--] | [-----] | [--] | [---] |
| @semodough | [--] | [------] | [--] | [---] |
| @seedytx19 | [--] | [-----] | [--] | [--] |
| @Mikeptyg | [--] | [--] | [--] | [--] |
| @adamfeuerstein | [--] | [-------] | [--] | [--] |
| @CamillusMiura | [--] | [---] | [--] | [--] |
| @Barmon81512 | [--] | [--] | [--] | [--] |
| @WolfOfPathogens | [--] | [--] | [--] | [--] |
Sentiment: 71%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 71%
Daily Average: 85%
[--] Month: 71% +4%
[--] Months: 71% -15%
[--] Year: 71% -22%
1-Year High: 100% on 2025-02-19
1-Year Low: 11% on 2025-12-02
Most Supportive Themes:
- Strong Institutional Ownership and Insider Buying: (50%) The stock is trading at a significant discount to its cash value, with 87.7% institutional ownership and a recent insider buy of $6.35 million, indicating strong confidence from major investors.
- Promising Phase [--] Cancer Drug Development: (50%) The company is advancing a Phase [--] cancer drug, which represents a significant potential catalyst for growth and value appreciation.
Most Critical Themes:
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing